Is Traws Pharma, Inc. overvalued or undervalued?

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its valuation ratios, including a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. In comparison to peers, Catalyst Biosciences, Inc. is considered expensive with a P/E of 110.04, while Elutia, Inc. is classified as risky with a P/E of -2.83, highlighting Traws Pharma's relatively favorable position.
Despite the recent stock performance showing a significant decline year-to-date of -76.58% compared to a 14.49% return for the S&P 500, the long-term perspective over three years reveals a strong return of 136.36%, which suggests potential recovery and growth ahead. Overall, Traws Pharma, Inc. is positioned as an undervalued opportunity in the pharmaceuticals and biotechnology sector.